Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | 2C16H19NO3.2ClH.H2O |
| Molecular Weight | 637.591 |
| Optical Activity | ( + ) |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.Cl.Cl.CO[C@@H]1C[C@]23N(CC=C2C=C1)CCC4=C3CC(=O)OC4.CO[C@@H]5C[C@]67N(CC=C6C=C5)CCC8=C7CC(=O)OC8
InChI
InChIKey=NXXUXBHFMHIYCD-RXORCXBCSA-N
InChI=1S/2C16H19NO3.2ClH.H2O/c2*1-19-13-3-2-12-5-7-17-6-4-11-10-20-15(18)8-14(11)16(12,17)9-13;;;/h2*2-3,5,13H,4,6-10H2,1H3;2*1H;1H2/t2*13-,16-;;;/m00.../s1
| Molecular Formula | H2O |
| Molecular Weight | 18.0153 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C16H19NO3 |
| Molecular Weight | 273.327 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Beta-erythroidine is an organic heterotetracyclic indole alkaloid isolated from the seeds and other parts of Erythrina species. A drug used to produce muscle relaxation (excepting neuromuscular blocking agents). Its primary clinical and therapeutic use is the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. Also used for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in multiple sclerosis. Beta-erythroidine is a neuronal nicotinic acetylcholine receptor antagonist. The beta-erythroidine and its more potent derivative (2,7-dihydro) have been used as muscular relaxants in numerous clinical applications. This activity is attributed to a antagonistic action of the dihydro-beta-erythroidine with the nicotinic receptors of acetyl choline.
Originator
Approval Year
Sample Use Guides
Mice: b-erythroidine (i.p.) has a more potent action where the LD50 was 24
mg/kg and 29.5 mg/kg
Route of Administration:
Intraperitoneal
Beta-erythroidine is void of cytotoxicity in doses
up to 10 uM. Beta-erythroidine induced significant estrogenic activity starting from 1 uM. Beta-erythroidine induced a significant
and dose-dependent activation of luciferase reporter gene activity
in U2OS-ERα cells starting from 10 nM.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 07:55:40 GMT 2023
by
admin
on
Sat Dec 16 07:55:40 GMT 2023
|
| Record UNII |
9SX70D97WU
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
6045-45-0
Created by
admin on Sat Dec 16 07:55:40 GMT 2023 , Edited by admin on Sat Dec 16 07:55:40 GMT 2023
|
PRIMARY | |||
|
9SX70D97WU
Created by
admin on Sat Dec 16 07:55:40 GMT 2023 , Edited by admin on Sat Dec 16 07:55:40 GMT 2023
|
PRIMARY | |||
|
76962898
Created by
admin on Sat Dec 16 07:55:40 GMT 2023 , Edited by admin on Sat Dec 16 07:55:40 GMT 2023
|
PRIMARY | |||
|
m5008
Created by
admin on Sat Dec 16 07:55:40 GMT 2023 , Edited by admin on Sat Dec 16 07:55:40 GMT 2023
|
PRIMARY | Merck Index |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
||
|
ANHYDROUS->SOLVATE |
|
